Adma Biologics, INC Form 4 insider transactions

Kaitlin M. Kestenberg-Messina, COO and SVP, Compliance of ADMA Biologics, reports the withholding of shares to cover tax obligations upon vesting of restricted stock units.

Adam Grossman, CEO of ADMA Biologics, reports the withholding of shares to cover tax obligations upon vesting of restricted stock units.

Lawrence P. Guiheen, a director at ADMA Biologics, exercised stock options and sold shares of common stock on September 9, 2024.

Kaitlin Kestenberg-Messina, COO and SVP of Compliance at ADMA Biologics, reported the acquisition and disposition of common stock and derivative securities on August 30, 2024.

Director Jerrold Grossman reports exercising options and selling shares of ADMA Biologics, Inc. common stock on August 29, 2024.

Adam Grossman, CEO of ADMA Biologics, exercised stock options and sold shares of common stock on August 26 and 27, 2024.

Director Young Kwon of ADMA Biologics, Inc. sold 60,000 shares of common stock at an average price of $18.26 on August 23, 2024.

Kaitlin Kestenberg-Messina, COO and SVP of Compliance at ADMA Biologics, reports the withholding of shares to cover tax obligations upon the vesting of restricted stock units.

CFO and Treasurer of ADMA Biologics, Brad L. Tade, reports the acquisition of restricted stock units and stock options, increasing his beneficial ownership in the company.

Kaitlin M. Kestenberg-Messina, COO and SVP of Compliance at ADMA Biologics, reports the withholding of shares to cover tax obligations upon vesting of restricted stock units.

Adam Grossman, President, CEO, and Interim CFO of ADMA Biologics, reports the withholding of shares to cover tax obligations upon the vesting of restricted stock units.

Adam Grossman, CEO of ADMA Biologics, reports changes in beneficial ownership of company stock due to a court-approved divorce settlement.

Kaitlin Kestenberg-Messina, COO and SVP of Compliance at ADMA Biologics, reports acquisition and disposal of ADMA common stock and stock options.

Adam Grossman, President, CEO, and Interim CFO of ADMA Biologics, reports changes in beneficial ownership of company stock due to tax withholding upon vesting of restricted stock units.

Steve Elms, a director at ADMA Biologics, sold a significant number of shares in two transactions on March 18 and 19, 2024.

Director Steve Elms sold ADMA Biologics shares in multiple transactions between March 13 and March 15, 2024.

Brian Lenz, EVP and CFO of ADMA Biologics, reports disposing of shares to cover tax obligations related to vesting restricted stock units (RSUs).

Adam Grossman, CEO of ADMA Biologics, reports the disposal of shares to cover tax obligations related to vesting restricted stock units (RSUs).

Adam Grossman, CEO of ADMA Biologics, reports the disposition of 9,588 shares of common stock to cover tax obligations upon vesting of Restricted Stock Units (RSUs).

Brian Lenz, EVP and CFO of ADMA Biologics, disposed of 4,935 shares of common stock on February 29, 2024, to cover tax obligations related to vesting restricted stock units.

Alison Finger, a director at ADMA Biologics, reported the acquisition of restricted stock units and stock options on February 26, 2024.

Adam Grossman, CEO of ADMA Biologics, reports the acquisition of restricted stock units and stock options, along with existing holdings.

Director Jerrold Grossman reports acquisition of ADMA Biologics stock and stock options, along with details of beneficial ownership.

Director Young Kwon reports acquisition of restricted stock units and stock options in ADMA Biologics, along with adjustments to existing holdings.

Director Bryant Fong reports acquisition of restricted stock units and stock options in ADMA Biologics, along with adjustments to direct ownership.

Director Lawrence P. Guiheen reports acquisition of restricted stock units and stock options in ADMA Biologics, along with adjustments to existing holdings.

Director Steve Elms reports acquisition of ADMA Biologics stock and options, including restricted stock units and stock options, while disclaiming beneficial ownership of shares held by Aisling Capital II LP except to the extent of his pecuniary interest.

Brian Lenz, EVP and CFO of ADMA Biologics, disposed of 8,257 shares of common stock on February 25, 2024, to cover tax obligations related to vesting restricted stock units.

Adam Grossman, President and CEO of ADMA Biologics, reports disposition of shares to cover tax obligations upon vesting of restricted stock units.